MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 599131 | Name: Lobeglitazone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lobeglitazone, also known as CKD-501, is an antidiabetic drug in the thiazolidinedione class of drugs. As an agonist for both PPARα and PPARγ, it works as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin.

Chemical Structure

Lobeglitazone
Lobeglitazone
CAS#607723-33-1 (free base)

Theoretical Analysis

MedKoo Cat#: 599131

Name: Lobeglitazone

CAS#: 607723-33-1 (free base)

Chemical Formula: C24H24N4O5S

Exact Mass: 480.1467

Molecular Weight: 480.53

Elemental Analysis: C, 59.99; H, 5.03; N, 11.66; O, 16.65; S, 6.67

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
607723-33-1 (free base) 763108-62-9 (Sulfate)
Synonym
Lobeglitazone; CKD-501; CKD 501; CKD501;
IUPAC/Chemical Name
5-(4-(2-((6-(4-methoxyphenoxy)pyrimidin-4-yl)(methyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
InChi Key
CHHXEZSCHQVSRE-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30)
SMILES Code
COc1ccc(Oc2ncnc(N(CCOc3ccc(CC4SC(NC4=O)=O)cc3)C)c2)cc1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 480.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Joshi S, Tandon M, Kodgule R, Wu W, Jadhao V, Suryawanshi S, Barkate H. Randomized, Double-blind, Phase III Trial of Lobeglitazone Add-on to Metformin in Type 2 Diabetes (SENSITIZE INDIA). J Assoc Physicians India. 2024 Jan;72(1):32-42. doi: 10.59556/japi.71.0445. PMID: 38736072. 2: Kim WJ, Kil BJ, Lee C, Kim TY, Han G, Choi Y, Kim K, Shin CH, Park SY, Kim H, Kim M, Huh CS. B. longum CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice. Gut Microbes. 2024 Jan-Dec;16(1):2319889. doi: 10.1080/19490976.2024.2319889. Epub 2024 Feb 23. PMID: 38391178; PMCID: PMC10896159. 3: M B Jr, S S Sr, R R Jr. Lobeglitazone and Its Therapeutic Benefits: A Review. Cureus. 2023 Dec 6;15(12):e50085. doi: 10.7759/cureus.50085. PMID: 38186506; PMCID: PMC10770577. 4: Choe HJ, Oh HR, Bu D, An N, Scherer PE, An Z, Lim S. Evaluation of the efficacy of a combination of dapagliflozin and lobeglitazone on glucose concentrations and body fat in patients with type 2 diabetes: Location-F study. Diabetes Obes Metab. 2024 Mar;26(3):1114-1119. doi: 10.1111/dom.15388. Epub 2023 Dec 11. PMID: 38073421. 5: Dutta D, Kadian J, Maisnam I, Kumar A, Bhattacharya S, Sharma M. Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta- Analysis. Indian J Endocrinol Metab. 2023 Jul-Aug;27(4):286-295. doi: 10.4103/ijem.ijem_17_23. Epub 2023 Aug 28. PMID: 37867986; PMCID: PMC10586552. 6: Seo HY, Lee SH, Park JY, Han E, Han S, Hwang JS, Kim MK, Jang BK. Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver. PLoS One. 2023 Aug 24;18(8):e0290532. doi: 10.1371/journal.pone.0290532. PMID: 37616215; PMCID: PMC10449201. 7: Hong JH, Moon JS, Seong K, Lim S. Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study. Diabetes Res Clin Pract. 2023 Sep;203:110872. doi: 10.1016/j.diabres.2023.110872. Epub 2023 Aug 11. PMID: 37574137. 8: Lee YK, Oh TJ, Lee JI, Choi BY, Cho HC, Jang HC, Choi SH. Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model. Eur J Pharmacol. 2023 Oct 15;957:175946. doi: 10.1016/j.ejphar.2023.175946. Epub 2023 Aug 2. PMID: 37541370. 9: Patel T, Patel V. Thiazolidinediones: Recent Development in Analytical Methodologies. J Chromatogr Sci. 2023 Aug 3:bmad058. doi: 10.1093/chromsci/bmad058. Epub ahead of print. Erratum in: J Chromatogr Sci. 2023 Sep 14;: PMID: 37539627. 10: Yoo J, Jeon J, Baik M, Kim J. Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case- control study. Cardiovasc Diabetol. 2023 May 5;22(1):106. doi: 10.1186/s12933-023-01841-4. PMID: 37147722; PMCID: PMC10163714. 11: Kim H, Kim CO, Park H, Park MS, Kim D, Hong T, Shin Y, Jin BH. Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects. Transl Clin Pharmacol. 2023 Mar;31(1):59-68. doi: 10.12793/tcp.2023.31.e4. Epub 2023 Mar 23. PMID: 37034122; PMCID: PMC10079507. 12: Gangopadhyay KK, Singh AK. Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal. Diabetes Metab Syndr. 2023 Apr;17(4):102747. doi: 10.1016/j.dsx.2023.102747. Epub 2023 Mar 21. PMID: 36966544. 13: Singh AK, Singh R, Gangopadhyay KK. Letter to the Editor regarding articles on lobeglitazone. Diabetes Metab Syndr. 2023 Aug;17(8):102727. doi: 10.1016/j.dsx.2023.102727. Epub 2023 Mar 2. PMID: 36934031. 14: Joshi SR, Das S, Xaviar S, Samajdar SS, Saha I, Sarkar S, Mukherjee S, Tripathi SK, Pal J, Chatterjee N. Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab Syndr. 2023 Jan;17(1):102703. doi: 10.1016/j.dsx.2022.102703. Epub 2023 Jan 2. PMID: 36634469. 15: Dutta D, Bhattacharya S, Kumar M, Datta PK, Mohindra R, Sharma M. Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis. Diabetes Metab Syndr. 2023 Jan;17(1):102697. doi: 10.1016/j.dsx.2022.102697. Epub 2022 Dec 23. PMID: 36580702. 16: Seo DH, Suh YJ, Cho Y, Ahn SH, Seo S, Hong S, Lee YH, Choi YJ, Lee E, Kim SH. Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice. Yonsei Med J. 2022 Sep;63(9):825-833. doi: 10.3349/ymj.2022.63.9.825. PMID: 36031782; PMCID: PMC9424781. 17: Gunasinghe J, Hwang SS, Yam WK, Rahman T, Wezen XC. In-silico discovery of inhibitors against human papillomavirus E1 protein. J Biomol Struct Dyn. 2023 Jul-Aug;41(12):5583-5596. doi: 10.1080/07391102.2022.2091659. Epub 2022 Jun 24. PMID: 35751129. 18: Ryang S, Kim SS, Bae JC, Han JM, Kwon SK, Kim YI, Nam-Goong IS, Kim ES, Kim MK, Lee CW, Yoo S, Koh G, Kwon MJ, Park JH, Kim IJ. A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study. Diabetes Obes Metab. 2022 Sep;24(9):1800-1809. doi: 10.1111/dom.14766. Epub 2022 Jun 9. PMID: 35581902; PMCID: PMC9541308. 19: Kim BY, Kwon HS, Kim SK, Noh JH, Park CY, Park HK, Song KH, Won JC, Yu JM, Lee MY, Lee JH, Lim S, Chun SW, Jeong IK, Chung CH, Han SJ, Kim HS, Min JY, Kim S. A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2022 Nov;46(6):855-865. doi: 10.4093/dmj.2021.0264. Epub 2022 Mar 8. PMID: 35255547; PMCID: PMC9723193. 20: Park J, Kim CO, Oh ES, Lee JI, Kim JK, Ahn SH, Kim DY, Kim SU, Kim BK, Chung YE, Kim SM, Park MS. Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. Clin Pharmacol Drug Dev. 2022 May;11(5):576-584. doi: 10.1002/cpdd.1045. Epub 2022 Mar 7. PMID: 35255191.